montelukast / Generic mfg. - LARVOL DELTA

First-line treatment with low-dose ruxolitinib, pirfenidone, and low-dose calcineurin inhibitors leads to significant improvement in patients with bronchiolitis obliterans syndrome after allogeneic transplantation (ASH 2025) - "Traditional treatments for BOS rely on glucocorticoids combined with FAM regimens ( fluticasone + azithromycin + montelukast ) and calmodulin phosphatase inhibitors ( CNIs ), but they have limited efficacy with an even lower overall remission rate ( ORR ) and poor prognosis once progression to steroid-refractory cGVHD (SR-cGVHD) is achieved...Methods A retrospective analysis of 14 patients, 11 males and 3 females, with a median age of 19 years (7-54 years), who underwent hematopoietic stem cell transplantation combined with BOS at Henan Cancer Hospital from 2018 to 2025, including 6 cases of mild BOS, 3 cases of moderate BOS, 5 cases of severe BOS, Among them, 6 cases of mild, 3 cases of moderate, and 5 cases of severe BOS were treated with low-dose rucotinib ( 5 mg qd po) combined with piroxicam (200 mg tid po), small-dose CNI (half of the effective therapeutic concentration), and FAM first-line treatment...Conclusions In conclusion, the first-line treatment of BOS..."

Clinical • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Transplantation

A multicentre UK snapshot audit of symptom burden in patients with indolent systemic mastocytosis utilising the ISM-SAF © (ASH 2025) - "Medications included H1 antihistamines (n=89), H2 antihistamines (n=49), proton pump inhibitors (n=22), sodium cromoglicate (n=23), montelukast (n=12), oral corticosteroid (n=1) and omalizumab (n=3). Of the 101 patients, median age at diagnosis was 46 years (range 11-76) with female predominance (62.4%). Median time to ISM diagnosis was 4.1 years (range 0.1-55.6). Median latest serum tryptase was 37.5 mcg/L (range 7.9-196; n=99) and 2 patients had levels >200 mcg/L."

Clinical • Hematological Disorders • Hematological Malignancies • Musculoskeletal Pain • Osteoporosis • Rheumatology • KIT

Motixafortide + G-CSF hematopoietic stem cell mobilization in patients with multiple myeloma following quadruplet induction therapy (ASH 2025) - P1, P3 | "All patients received"enhanced" premeds with: loratadine (10 mg, PO), famotidine (20 mg, PO) and montelukast (10 mg, PO)daily on Day 1-5; plus acetaminophen (975mg, PO), hydrocortisone (200 mg, IV), diphenhydramine (25mg, IV) and famotidine (20 mg, IV) on Day 4 (30-45 mins pre-M). Meanwhile,enhanced premeds were associated with a low rate of AEs relative to standard premeds. Ongoingextended immunophenotyping may shed insight into the mechanism of impaired HSC mobilization post-quad induction, possibly via targeted depletion of a large population of CD38+ HSCs within the CD34+graft."

Clinical • Dermatology • Hematological Malignancies • Multiple Myeloma • Pruritus • CD34

Evaluating the efficacy of montelukast in reducing the incidence and severity of monoclonal antibodies-associated infusion reactions (Phase II Study) (ASH 2025) - P2 | "Mean LDH was within normal limits (182 IU/L; range 99–451).A total of 198 MAB doses administered: Rituximab: 100(50.5%)Daratumumab: 42(21%)Obinutuzumab: 18(9%)Blinatumomab: 18(9%)Gemtuzumab: 14(7%)Elotuzumab: 6(3%)All patients received at least one cycle (Cycle 1), with rituximab being the most frequently used (21patients). Due to the low number of events, no significant associations wereidentified for reactions in Cycles 2–6.Compared to published registration trial data for the included MABs, adding MKA was associated with a43% risk reduction of infusion reactions (p < 0.001).Conclusion10 mg MKA added to the premedication of MAB infusion is well tolerated and significantly reduces therisk of MCAAEsPatients with a history of atopy or medication allergy are at high risk for infusion reactions during the firstcycle of therapy, even with MKA premedication. This subgroup may benefit from closer monitoring andfurther intervention strategies."

Clinical • P2 data • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • B Cell Lymphoma • Burkitt Lymphoma • Chronic Lymphocytic Leukemia • CNS Disorders • Depression • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Immunology • Infectious Disease • Lymphoma • Marginal Zone Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Psychiatry

The single-center retrospective analysis of steroid-free rmap regimen (ruxolitinib, montelukast, azithromycin, and pirfenidone) treating moderate-to-severe bronchiolitis obliterans syndrome (BOS). (ASH 2025) - "The steroid-free RMAP regimen demonstrated promising efficacy in moderate-to-severe BOS,enabling rapid steroid withdrawal while improving quality of life and long-term survival. However, giventhe small sample size and retrospective design, further prospective studies are warranted for validation."

Retrospective data • Bone Marrow Transplantation • Infectious Disease • Pneumonia • Pulmonary Disease • Respiratory Diseases

Improved hematopoietic stem cell mobilization for gene therapy using single agent motixafortide in sickle cell disease (ASH 2025) - P1 | "Currently, HSC mobilizationfor SCD is limited to single agent plerixafor (P), a CXCR4 antagonist, since G-CSF is associated with anincreased risk of vaso-occlusive events (VOEs) and death...The median total number of CD34+ cellscollected/day with P was 2.6 x 106/kg compared to 6.8 x 106/kg with M. M was used first line in 3 patientswith preexisting clinical concerns precluding multiple collection cycles...To mitigate known local injection site and potential systemicreactions to M, all patients received prophylactic H-1 and H-2 antagonists and acetaminophen, with 82%receiving additional montelukast...Ongoing clinical trials of M in SCD are examining safety, mobilization efficacy,optimal dose timing, and editing potential (NCT06442761; NCT05618301). Additional studies arewarranted to determine the ideal prophylactic medication regimen."

Gene therapy • Dermatology • Gene Therapies • Genetic Disorders • Hematological Disorders • Hematological Malignancies • Multiple Myeloma • Pruritus • Sickle Cell Disease • Urticaria • CD34

BH09 Rapid resolution of chronic spontaneous urticaria with ritlecitinib in a patient with alopecia universalis. (PubMed, Br J Dermatol) - "Initial management included high-dose fexofenadine, famotidine, montelukast and omalizumab...Pulsed dexamethasone provided modest improvement in her urticaria symptoms but did not alter the progression of her alopecia...While JAK inhibitors are not established as a standard treatment for CSU, limited case series have documented the use of tofacitinib in refractory cases...The rapid and sustained symptom resolution observed in this patient suggests the potential of ritlecitinib as a novel therapeutic option for refractory CSU. Further investigation is warranted to evaluate its broader clinical applicability and efficacy in CSU management."

Journal • Alopecia • Asthma • Chronic Spontaneous Urticaria • Dermatology • Endocrine Disorders • Immunology • Pulmonary Disease • Respiratory Diseases • Urticaria

Pakistan's increasing SMOG and the use of Montelukast: Weighing airway benefits and neuropsychiatric risks. (PubMed, J Pak Med Assoc) - No abstract available

Journal • Psychiatry

Montelukast as a novel therapeutic approach in metastatic uveal melanoma harboring a CYSLTR2 mutation: a translational case report. (PubMed, ESMO Open) - "This is the first published case suggesting a potential role for leukotriene receptor antagonists in CYSLTR2-mutant UM. These findings support further preclinical and clinical investigation of montelukast as a repurposed therapy in this challenging disease entity."

IO biomarker • Journal • Eye Cancer • Melanoma • Oncology • Solid Tumor • Uveal Melanoma • CYSLTR2

Changes in Immunosuppressive Treatment of Chronic Graft-Versus-Host Disease: Results from a Survey within Allogeneic Hematopoietic Stem Cell Transplant Centers in Germany, Austria, and Switzerland (ASH 2024) - "Since the last survey, ruxolitinib (rux) has been approved and other agents are explored in treatment of cGVHD...For BOS, systemic and inhalative corticosteroids, montelukast and azithromycin (FAM), rux (14/19), ECP (16/19), CNI (9/19), and abatacept (9/19) are frequently applied agents, while belumosudil (7/19), imatinib (5/19) and ibrutinib (2/19) are used as salvage option in selected patients. In case of new sclerotic manifestations after failure of 2nd line treatment including steroids, CNI and rux, most centers would use ECP (13/19), whereas subsequent or alternative salvage treatment of sclerotic manifestations remains heterogenous comprising belumosudil (12/19), ibrutinib (5/19), imatinib (5/19), rituximab (4/19), cyclosporine (3/19), tacrolimus (3/19), everolimus (3/19), sirolimus (3/19), MTX (3/19) and MMF (3/19)...ECP is used in case of contraindication for rux and both agents are also used in progressive onset cGVHD. In contrast, treatment of BOS and..."

Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Disorders • Immunology • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Transplantation

Efficacy of a Combination Therapy of Montelukast and Antihistamines in Allergic Rhinitis: A Systematic Review and Network Meta-Analysis. (PubMed, Allergy Asthma Immunol Res) - "The treatment strategies included montelukast alone, antihistamine monotherapies (loratadine, desloratadine, levocetirizine, and fexofenadine), their respective combinations with montelukast, including bilastine. Although some comparisons require cautious interpretation, montelukast-based combination therapy demonstrated greater efficacy than monotherapy for multiple AR symptoms. These results highlight the importance of selecting therapeutic strategies based on the predominant symptom profile of individual patients."

Journal • Retrospective data • Review • Allergic Rhinitis • Conjunctivitis • Immunology • Inflammation • Ocular Infections • Ocular Inflammation • Ophthalmology

Modulating the lung-gut axis: A randomized controlled trial of Xie Bai Zeng Ye decoction on intestinal flora and mucosal immunity in children with post-infectious cough. (PubMed, Medicine (Baltimore)) - "This exploratory study suggests that XBZY may be a promising treatment option for children with post-infectious cough characterized by lung heat and Yin deficiency. Compared with Montelukast Sodium, XBZY demonstrated superior short-term improvements in cough resolution, symptom relief, quality of life, intestinal barrier function, and gut microbiota modulation, while maintaining good safety. These findings highlight the potential role of the lung-gut axis in pediatric respiratory care and support the integration of TCM-based strategies; however, larger, blinded, and longer-term studies are needed to validate these results and assess their broader clinical applicability."

Clinical • Journal • Cough • Pediatrics • Respiratory Diseases

Montelukast Use and the Risk of Neuropsychiatric Adverse Events in Children. (PubMed, Pediatrics) - No abstract available

Adverse events • Journal • Psychiatry

Letter to the editor:" The clinical outcome of Montelukast versus co-enzyme Q10 in adult patients with sepsis: A randomized controlled clinical trial". (PubMed, J Crit Care) - No abstract available

Clinical • Clinical data • Journal • Infectious Disease • Septic Shock

Trial in Progress: Phase 2 Study of Subcutaneous Isatuximab, Administered By an on-Body Delivery System, in Combination with Weekly Carfilzomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (SubQSA) (ASH 2024) - P1, P2 | "Intravenous (IV) Isa is currently approved to treat relapsed and/or refractory multiple myeloma (RRMM) in combination with pomalidomide and dexamethasone (Isa-Pd) or carfilzomib and dexamethasone (Isa-Kd)...In addition to dexamethasone, patients will receive premedication for IRs with montelukast (C1 only), acetaminophen, and diphenhydramine...ORR will be summarized with a two-sided 95% confidence interval by the Clopper-Pearson method. This study is not yet recruiting."

Clinical • Combination therapy • P2 data • Hematological Malignancies • Lymphoma • Multiple Myeloma • Oncology

Can measures of small airway dysfunction aid with the diagnosis or management of asthma exacerbations? – A systematic review (BTS WM 2025) - "The SDP begins with stepwise withdrawal of add-on controller therapies including montelukast, theophylline, long-acting muscarinic antagonists (LAMA) inhalers and nasal corticosteroids followed by incremental dose reduction of high-dose inhaled corticosteroids and long-acting β2-agonists (HD-ICS/LABA) inhalers and cessation of short-acting β2-agonists (SABA) and nebulisers...Reference Global Initiative for Asthma (GINA) (2024) Global strategy for asthma management and prevention . Available at: https://ginasthma.org/gina-reports/ (Accessed: 11 June 2025)."

Review • Asthma • Immunology • Respiratory Diseases

Cysteinyl leukotriene receptor 1 regulates cellular glucose levels in human retinal cells. (PubMed, Mol Vis) - "Primary human ECs, PCs, and the ARPE-19 cell line were cultured under standard (5.5 mmol/l glucose + 27.5 mmol/l mannitol) and high-glucose (33.0 mmol/l) conditions in the absence and presence of the specific CysLTR1 antagonists montelukast and zafirlukast for 1, 3, and 7 days. Interestingly, the effect of CysLTR1 activity on glucose levels was reversed under acute metabolic stress. Thus, the activity of CysLTR1 appears to be more complex in terms of glucose metabolism and needs to be studied in more detail."

Journal • Diabetes • Diabetic Retinopathy • Metabolic Disorders • Retinal Disorders • Type 2 Diabetes Mellitus

Matrix Metalloproteinase-9 (MMP-9) as a Therapeutic Target: Insights into Molecular Pathways and Clinical Applications. (PubMed, Pharmaceutics) - "Anti-inflammatory and respiratory drugs, including glucocorticoids, phosphodiesterase-4 (PDE4) inhibitors, macrolide antibiotics, montelukast, and nonsteroidal anti-inflammatory drugs (NSAIDs), suppress MMP-9-driven airway inflammation and pathological tissue remodeling in asthma, COPD, and acute lung injury. Tetracycline derivatives, particularly sub-antimicrobial dose doxycycline, directly inhibit MMP-9 activity and are clinically validated in the treatment of periodontal disease and vascular remodeling. Hormone-related therapies such as rapamycin, estradiol, and tamoxifen exert tissue- and disease-specific effects on MMP-9 within endocrine and oncologic pathways...Taken together, these findings position MMP-9 as a modifiable and clinically relevant therapeutic target. The systematic integration of approved pharmacologic agents with lifestyle and nutritional interventions into disease-specific treatment paradigms may facilitate safer, context-specific modulation of..."

Journal • Review • Acute Lung Injury • Asthma • Atherosclerosis • Cardiovascular • Chronic Obstructive Pulmonary Disease • CNS Disorders • Dental Disorders • Immunology • Oncology • Periodontitis • Pulmonary Disease • Respiratory Diseases • MMP9

Mechanistic Insights Into the Modulation of Gut Microbiota and ERK Signaling by Morusin in Juvenile Rats with Post-Infectious Cough. (PubMed, J Inflamm Res) - "Current therapies, such as montelukast sodium (MAS), offer only partial symptom relief and do not target the underlying inflammatory and microbiota-driven mechanisms...Morusin alleviates PIC through systemic, mucosal, and behavioral improvements, combined with unique modulation of gut microbiota and ERK signaling across the lung-gut axis. These findings highlight morusin's novel mechanistic advantage over MAS and support its potential as a translational therapy for pediatric PIC."

Journal • Preclinical • Chronic Cough • Cough • Infectious Disease • Inflammation • Mood Disorders • Pediatrics • Psychiatry • Pulmonary Disease • Respiratory Diseases • IL10 • IL4 • IL6

Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE Trial (clinicaltrials.gov) - P4 | N=94 | Recruiting | Sponsor: Emory University | Not yet recruiting ➔ Recruiting

Enrollment open • Allergy • Hematological Malignancies • Multiple Myeloma • Oncology

Prevalence and Factors Associated with Poor Sleep Quality in Chronic Obstructive Pulmonary Disease Patients: Cross-Sectional Study (APSR 2025) - "Higher CAT and mMRC scores correlated with worse sleep quality. GOLD stage II and Montelukast were associated with decreasing risk of poor sleep quality."

Clinical • Observational data • Chronic Obstructive Pulmonary Disease • CNS Disorders • Depression • Excessive Daytime Sleepiness • Immunology • Obstructive Sleep Apnea • Psychiatry • Pulmonary Disease • Respiratory Diseases • Sleep Disorder

Sarcoidosis vs. Sarcoid reactions: Decision is Up to The Clinician (APSR 2025) - "Case Report : A 33-year-old male with pollen-induced allergic rhinitis (pollinosis) was diagnosed in 2021 with severe, controlled bronchial asthma, aspirin-exacerbated respiratory disease, and chronic rhinosinusitis with nasal polyps (CRSwNP). Following inhaled budesonide/formoterol and intermittent montelukast, asthma was controlled. Given recurrent CRSwNP, dupilumab was initiated in March 2022, with a positive clinical response...Differential diagnosis between sarcoidosis and DISR warrants consideration. The etiologies and medications associated with DISR require further investigation and incorporation into clinical guidelines."

Clinical • Allergic Rhinitis • Asthma • Chronic Rhinosinusitis With Nasal Polyps • Fibrosis • Immunology • Infectious Disease • Inflammation • Nasal Polyps • Otorhinolaryngology • Pulmonary Disease • Respiratory Diseases • Sarcoidosis • Sinusitis • Tuberculosis

The effect of CysLTR1 inhibition on cells of the retinal neurovascular unit in 5xFAD Alzheimer mice. (PubMed, Exp Eye Res) - "Therefore, the present study investigated the effects of the cysteinyl leukotriene receptor 1 (CysLTR1) antagonist montelukast (MTK) on retinal NVU cells in the 5xFAD mouse model of AD...In conclusion, the present study revealed minor AD-associated changes in retinal NVU cells in the 5xFAD mouse model. MTK treatment increased dose-independently PC coverage, but it remains to be clarified whether this affects the vessel tightness and blood flow."

Journal • Preclinical • Alzheimer's Disease • CNS Disorders • Inflammation

Effects of montelukast on allergic rhinitis in children: a systematic review and meta-analysis. (PubMed, Am J Transl Res) - "Montelukast improves the total effective rate and clinical symptoms of pediatric AR with a favorable safety profile."

Journal • Retrospective data • Review • Allergic Rhinitis • Immunology • Inflammation • Pediatrics

Dual Biologic Therapy In Eosinophilic Esophagitis: A Case Report (ACAAI 2025) - "Despite treatment with dexlansoprazole, ranitidine, montelukast, cetirizine, budesonide (swallowed), and multiple food elimination diets, she experienced persistent retrosternal chest pain, dysphagia, abdominal pain, nausea and recurrent oral sores...After unsuccessful trials of crisaborole and cyclosporine, dupilumab was started...Discussion The 2025 American College of Gastroenterology guidelines support dupilumab use in EoE, however no recommendation exists for or against benralizumab use. This case highlights the potential role of dual biologic use, particularly in patients with severe EoE and coexisting atopic disease, though further research is needed."

Case report • Clinical • Allergic Rhinitis • Asthma • Contact Dermatitis • Dermatitis • Dermatology • Eosinophilic Esophagitis • Gastrointestinal Disorder • Immunology • Inflammation • Respiratory Diseases • IL13 • IL4 • IL5